Novadaq Technologies Inc.

Novadaq Technologies Inc.

August 29, 2011 16:01 ET

Novadaq to Present at September Investor Healthcare Conferences

TORONTO, ONTARIO--(Marketwire - Aug. 29, 2011) - Novadaq® Technologies Inc. (TSX:NDQ), a developer of real-time imaging systems for use in the operating room, announced today that Dr. Arun Menawat, the company's president and chief executive officer, will present Novadaq's corporate overview at three investor healthcare conferences in September. The presentations will be broadcast live on the Company's website at under the "Events" tab in the "Investors" section.

September 8 at 2:40 p.m. Eastern Time: Dr. Menawat will present at the Stifel Nicolaus Annual Healthcare Conference 2011. The conference is scheduled at the Four Seasons Hotel in Boston, September 7-9.
September 12 at 10:25 a.m. Eastern Time: Dr. Menawat will also present at the Rodman & Renshaw Annual Global Investment Conference. The conference is scheduled at the Waldorf Astoria Hotel in New York, September 11-13.
September 28 at 11:30 a.m. Eastern Time: Dr. Menawat will present at the Sixth Annual JMP Securities Conference at 11:30 a.m. Eastern Time. The conference is scheduled at the St. Regis Hotel in New York, September 27-28.

About Novadaq Technologies Inc.

Novadaq Technologies develops and markets real-time fluorescence imaging technologies for use in the operating room. The Company's core technology platform, SPY imaging, provides clinically relevant, anatomic and physiologic images during a wide variety of complex open and minimally invasive surgical ("MIS") procedures. SPY empowers surgeons treating life-threatening illnesses such as breast, colon and other cancers and cardiovascular disease to more effectively treat vascular blockages and assess tissue perfusion. More than 40 peer-reviewed publications demonstrate that SPY imaging leads to fewer post-operative complications and reduced hospital costs. The SPY imaging System is cleared by the United States Food and Drug Administration ("FDA") for real-time use during open and MIS surgical procedures. The endoscopic SPY System combines all of the capabilities of SPY imaging with state-of-the-art high definition ("HD") visible light visualization offered by conventional endoscopes. Novadaq announced its first alliance with Intuitive Surgical®, Inc., in January 2009, to integrate SPY Imaging into the 3-D HD imaging capabilities of the da Vinci® Surgical Robotic System. The integrated system received FDA 510(k) clearance to market in February 2011. In addition, in September 2010, Novadaq entered into an exclusive North American sales and marketing alliance with LifeCell™ Corporation, a Kinetic Concepts ("KCI"), Inc. Company, for SPY in open plastic and reconstructive, gastrointestinal and head and neck surgery. Novadaq's cardiac surgery products, including SPY imaging for cardiac applications and a Heart Laser™ System targeted at improving heart surgeries, are marketed through a direct sales team. For more information, please visit the Company's website at

Forward-Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, results of future clinical tests of PINPOINT, SPY endoscopic technology and the SPY Imaging System, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Investor Relations Contact
    Novadaq Technologies Inc.
    David C. Martin
    Vice President, Business Development and Investor Relations
    905-629-3822 ext: 218